Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2466
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study ; volume:22 ; number:1 ; day:30 ; month:11 ; year:2022 ; pages:1-9 ; date:12.2022
BMC pulmonary medicine ; 22, Heft 1 (30.11.2022), 1-9, 12.2022
- Urheber
-
Nio, Yuta
Ishida, Hiroo
Matsumoto, Natsumi
Kusumoto, Sojiro
Kubota, Yutaro
Tsunoda, Takuya
Sasaki, Yasutsuna
Fujita, Ken-ichi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12890-022-02249-8
- URN
-
urn:nbn:de:101:1-2023021209464221607713
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 13:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nio, Yuta
- Ishida, Hiroo
- Matsumoto, Natsumi
- Kusumoto, Sojiro
- Kubota, Yutaro
- Tsunoda, Takuya
- Sasaki, Yasutsuna
- Fujita, Ken-ichi
- SpringerLink (Online service)
Ähnliche Objekte (12)
EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report
Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer
Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer
EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report
Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer
Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer
EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report
Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer
Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology